Cargando…

Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review

Patient: Male, 16-year-old Final Diagnosis: Idiopathic intracranial hypertension • lupus anticoagulant-hypoprothrombinemia syndrome • pseudotumor cerebri • systemic lupus erythematosus Symptoms: Arthralgia • bleeding • epistaxis • headache • hematuria • visual acuity loss Medication: — Clinical Proc...

Descripción completa

Detalles Bibliográficos
Autores principales: Omer, Mohamed H., Salama, Hind, Alghaythi, Asim M., Alharbi, Abdullah A., AlJohani, Ghassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554927/
https://www.ncbi.nlm.nih.gov/pubmed/36207805
http://dx.doi.org/10.12659/AJCR.938051
Descripción
Sumario:Patient: Male, 16-year-old Final Diagnosis: Idiopathic intracranial hypertension • lupus anticoagulant-hypoprothrombinemia syndrome • pseudotumor cerebri • systemic lupus erythematosus Symptoms: Arthralgia • bleeding • epistaxis • headache • hematuria • visual acuity loss Medication: — Clinical Procedure: — Specialty: Hematology • Rheumatology OBJECTIVE: Rare disease BACKGROUND: Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is an exceptionally rare disease caused by prothrombin antibodies, resulting in reduced factor II levels. This disease can present with significant bleeding and is usually associated with autoimmune disorders, particularly systemic lupus erythematosus (SLE). There are currently no guidelines for the treatment of LAHPS, and corticosteroids remain the criterion standard therapy. Pseudotumor cerebri is a disease that involves an idiopathic rise in intracranial pressure in association with papilledema. The coexistence of pseudotumor cerebri with SLE is rare, with an overall incidence of 0.7%. CASE REPORT: A 16-year-old male initially presented to our hospital with nausea, headaches, and decreased visual acuity. He was diagnosed with pseudotumor cerebri based on the findings of papilledema and a raised opening pressure on lumbar puncture. Three months later, he presented with macroscopic hematuria and persistent epistaxis. Further investigation revealed a prolonged activated partial thromboplastin time and prothrombin time, along with positive LA and reduced Factor II levels, resulting in a diagnosis of LAHPS. The patient received a dose of 1 mg/kg/day of prednisolone along with hydroxychloroquine, and he had a complete recovery with cessation of bleeding and normalization of laboratory parameters. CONCLUSIONS: We are reporting a case of pseudotumor cerebri with a further presentation of LAHPS in a patient found to have SLE. As both associations are rare in the presence of SLE, it is vital to recognize them early to initiate adequate management and intervention to avoid life-threatening complications.